Taking financial relationships into account when assessing research

Accountability in Research

Volumn 20, Issue 3, 2013, Pages 184-205

  Resnik, David B ^a   Elliott, Kevin C ^b  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Bias; Conflict of interest; Disclosure policies; Financial relationships; Objectivity; Scientific research

Indexed keywords

ARTICLE; CONFLICT OF INTEREST; ECONOMICS; ETHICS; FINANCIAL MANAGEMENT; INTERPERSONAL COMMUNICATION; METHODOLOGY; ORGANIZATION AND MANAGEMENT; RESEARCH; RESEARCH ETHICS; STATISTICAL ANALYSIS;

CONFLICT OF INTEREST; DATA INTERPRETATION, STATISTICAL; DISCLOSURE; ETHICS, RESEARCH; FINANCIAL SUPPORT; RESEARCH; RESEARCH DESIGN;

EID: 84879454930     PISSN: 08989621     EISSN: 15455815     Source Type: Journal    
DOI: 10.1080/08989621.2013.788383     Document Type: Article

References (75)

1. Angell, M. (2005). The Truth about the Drug Companies. New York: Random House.
2. American Public Health Association. (2003). Supporting legislation for independent post-marketing phase IV comparative evaluation of pharmaceuticals. Washington, D.C.: APHA. Available at http://www.apha.org/advocacy/policy/policysearch/default.htm?id=1265. Last accessed November 8, 2011.
3. Association of American Universities. (2001). Report on Individual and Institutional Financial Conflict of Interest. Available at http://www.aau.edu/WorkArea/DownloadAsset.aspx?id=2678. Last accessed February 19, 2013.
4. Bekelman, J. E., Li, Y., and Gross, C. P. (2003). Scope and impact of financial conflicts of interest in biomedical research: a systematic review. Journal of the American Medical Association, 289: 454-465.
5. Bero, L. A. (2005). Tobacco industry manipulation of research. Public Health Reports, 120: 200-208.
6. Blum, J. A., Freeman, K., Dart, R. C., and Cooper R. J. (2009). Requirements and definitions in conflict of interest policies of medical journals. Journal of the American Medical Association, 302: 2230-2234.
7. Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., Day, R., Ferraz, M. B., Hawkey, C. J., Hochberg, M. C., Kvien, T. K., and Schnitzer, T. J.; VIGOR Study Group. (2000). Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. New England Journal of Medicine, 343: 1520-1558.
8. Borgert, C. J. (2007). Conflict of interest or contravention of science? Regulatory Toxicology and Pharmacology, 48: 4-5.
9. Chaudhry, S., Schroter, S., Smith, R., and Morris, J. (2002). Does declaration of competing interests affect readers' perceptions? A randomised trial. British Medical Journal, 325: 1391-1392.
10. Cho, M. K., Shohara, R., Schissel, A., and Rennie, D. (2000). Policies on faculty conflicts of interest at US universities. Journal of the American Medical Association, 284: 2203-2238.
11. Cialdini, R. B. (1993). Influence: The Psychology of Persuasion. New York: Quill William Morrow.
12. Conrad, J. and Becker, R. (2011). Enhancing credibility of chemical safety studies: Emerging consensus on key assessment criteria. Environmental Health Perspectives, 119: 757-764.
13. Cooper, R. J., Gupta, M., Wilkes, M. S., and Hoffman, J. R. (2006). Conflict of interest disclosure policies and practices in peer-reviewed biomedical journals. Journal of General Internal Medicine, 21: 1248-1252.
14. Cosgrove, L. and Krimsky, S. (2012). A comparison of DSM-IV and DSM-5 panel members' financial associations with industry: A pernicious problem persists. PLoS Medicine, 9(3): e1001190.
15. Cranor, C. (2008). Toxic Torts: Science, Law, and the Possibility of Justice. New York: Cambridge University Press.
16. De Angelis, C. D. (2000). Conflict of interest and the public trust. Journal of the American Medical Association, 284: 2237-2238.
17. De Angelis, C. and Fontanarosa, P. (2008). Impugning the integrity of medical science: The adverse effects of industry influence. Journal of the American Medical Association, 299: 1833-1835.
18. De Angelis, C. D., Drazen, J. M., Frizelle, F. A., Haug, C., Hoey, J., Horton, R., Kotzin, S., Laine, C., Marusic, A., Overbeke, A. J., Schroeder, T. V., Sox, H. C., and Van Der Weyden, M. B. International Committee of Medical Journal Editors. (2005). Is this clinical trial fully registered? A statement from the International Committee of Medical Journal Editors. New England Journal of Medicine, 352: 2436-2438.
19. Department of Health and Human Services. (2011). Responsibility of Applicants for Promoting Objectivity in Research for which Public Health Service Funding is Sought and Responsible Prospective Contractors. Federal Register 76, 165: 53256-53293.
20. Dickersin, K. (1990). The existence of publication bias and risk factors for its occurrence. Journal of the American Medical Association, 263: 1385-1389.
21. Easterbrook, P., Berlin, J., Gopalan, R., and Matthews, D. (1991). Publication bias in clinical research. Lancet, 337: 867-872.
22. Eisenberg, M. J., Blum, L. M., Filion, K. B., Rinfret, S., Pilote, L., Paradis, G., Joseph, L., Gervais, A., and O'Loughlin, J. (2010). The efficacy of smoking cessation therapies in cardiac patients: A meta-analysis of randomized controlled trials. Canadian Journal of Cardiology, 26: 73-79.
23. Elliott, K. C. (2008). Scientific judgment and the limits of conflict-of-interest policies. Accountability in Research, 15: 1-29.
24. Elliott, K. C. (2011). Is a Little Pollution Good for You? Incorporating Societal Values in Environmental Research. New York: Oxford University Press
25. Elliott, K. C. (2013). Selective ignorance and agricultural research. Science, Technology, and Human Values, 38: 328-350.
26. Elliott, K. C. and McKaughan, D. (2009). How values in discovery and pursuit alter theory appraisal. Philosophy of Science, 76: 598-611.
27. Elliott, K. C. and Volz, D. (2012). Addressing conflicts of interest in nanotechnology oversight: Lessons learned from drug and pesticide safety testing. Journal of Nanoparticle Research, 14: 664-668.
28. Fanelli, D. (2009). How many scientists fabricate and falsify research? A systematic review and meta-analysis of survey data. PLoS One, 4: e5738.
29. Friedberg, M., Saffran, B., Stinson, T., Nelson, W., and Bennett, C. (1999). Evaluation of conflict of interest in new drugs use in oncology. Journal of the American Medical Association, 282: 1453-1457.
30. Glantz, S. A., Slade, J., Bero, L. A., Hanauer, P., and Barnes, D. E. (eds.). (1998). The Tobacco Papers. Berkeley, CA: University of California Pres.
31. Golden Leaf Foundation. (2012). About us. Available at: http://www.goldenleaf.org/about.html. Last accessed December 27, 2012.
32. Goozner, M. (2004a). The $800 Million Pill. Berkeley, CA: University of California Press.
33. Goozner, M. (2004b). Study on failures to disclose conflicts of interest in Environmental Health Perspectives. Environmental Health Perspectives, 112: A794-A795.
34. Greenberg, D. (2001). Science, Money, and Politics. Chicago: University of Chicago Press.
35. Gupta, S. K. (2011). Intention-to-treat concept: a review. Perspectives in Clinical Research, 2: 109-112.
36. Healy, D. and Catell, D. (2003). Interface between authorship, industry, and science in the domain of therapeutics. British Journal of Psychology, 183: 22-27.
37. Hochster, H. (2008). The power of "p": on overpowered clinical trials and "positive" results. Gastrointestinal Cancer Research 2: 108-109.
38. James, M. J., Cook-Johnson, R. J., and Cleland, L. G. (2007). Selective COX-2 inhibitors, eicosanoid synthesis and clinical outcomes: A case study of system failure. Lipids 42: 779-785.
39. Journal of the American Medical Association. (2012). Instructions for Authors. Available at: http://jama.jamanetwork.com/public/instructionsForAuthors.aspx. Last accessed December 31, 2012.
40. Katz, D., Caplan, A. L., and Merz, J. F. (2003). All gifts large and small: Toward an understanding of the ethics of pharmaceutical industry gift-giving. American Journal of Bioethics, 3(3): 39-46.
41. Kesselheim, A. S., Robertson, C. T., Myers, J. A., Rose, S. L., Gillet, V., Ross, K. M., Glynn, R. J., Joffe, S., and Avorn, J. (2012). A randomized study of how physicians interpret research funding disclosures. New England Journal of Medicine, 367: 1119-1127.
42. Krimsky, S. (2003). Science in the Private Interest. Lanham, MD: Rowman and Littlefield.
43. Krimsky, S. and Rothenberg, L. S. (2001). Conflict of interest policies in science and medical journals: editorial practices and author disclosures. Science and Engineering Ethics, 7: 205-218.
44. Krimsky, S. (2012). Do financial conflicts of interest bias research? An inquiry into the ''funding effect'' hypothesis. Science, Technology, and Human Values, 20 September 2012 [epub ahead of print].
45. Lesser, L. I., Ebbeling, C. B., Goozner, M., Wypij, D., and Ludwig, D. S. (2007). Relationship between funding source and conclusion among nutrition-related scientific articles. PLoS Medicine, 4(1): e5.
46. Lexchin, J. (2012). Those who have the gold make the evidence: How the pharmaceutical industry biases the outcomes of clinical trials of medications. Science and Engineering Ethics 15 February 2012 [epub ahead of print].
47. Lexchin, J., Bero, L. A., Djulbegovic, B., and Clark, O. (2003). Pharmaceutical industry sponsorship and research outcome and quality: Systematic review. BMJ, 326: 1167-1170.
48. Loewenstein, G., Sah, S., and Cain, D. M. (2012). The unintended consequences of conflict of interest disclosure. Journal of the American Medical Association, 307: 669-670.
49. McCarty, L. S., Borgert, C. J., and Mihaich, E. M. (2012). Information quality in regulatory decision making: peer review versus good laboratory practice. Environmental Health Perspectives, 120: 927-934.
50. McCrary, S. V., Anderson, C. B., Jakovljevic, J., Khan, T., McCullough, L. B., Wray, N. P., and Brody, B. A. (2000). A national survey of policies on disclosure of conflicts of interest in biomedical research. New England Journal ofMedicine, 343: 1621-1666.
51. McGarity, T. and Wagner, W. (2008). Bending Science: How Special Interests Corrupt Public Health Research. New York: Cambridge University Press.
52. Michaels, D. (2008). Doubt Is Their Product. New York: Oxford University Press.
53. National Science Foundation. (2011). Conflict of Interest Policies. Available at: http://www.nsf.gov/pubs/policydocs/pappguide/nsf11001/aag_4.jsp. Last accessed December 17, 2012.
54. The PLoS Medicine Editors. (2010). A new policy on tobacco papers. PLoS Medicine, 7: e1000237.
55. Quik, M., Huang, L. Z., Parameswaran, N., Bordia, T., Campos, C., and Perez, X. A. (2009). Multiple roles for nicotine in Parkinson's disease. Biochemical Pharmacology, 78: 677.
56. Resnik, D. B. (2007). The Price of Truth: How Money Affect the Norms of Science. New York: Oxford University Press.
57. Resnik, D. B. (2009). Disclosing hidden sources of funding. Academic Medicine, 84: 1226-1228.
58. Resnik, D. B. and Shamoo, A. S. (2002). Conflicts of interest and the university. Accountability in Research, 9: 45-64.
59. Ridker, P. M and Torres, J. (2006). Reported outcomes in major cardiovascular clinical trials funded by for-profit and not-for-profit organizations: 2000-2005. Journal of the American Medical Association, 295: 2270-2274.
60. Rothman, K. J. (1993). Conflict of interest: the new McCarthyism in science. Journal of the American Medical Association, 269: 2782-2784.
61. Rothman, K. J. and Evans, S. (2005). Extra scrutiny for industry funded trials: JAMA's demand for an additional hurdle is unfair-and absurd. British Medical Journal, 331: 1350-1351.
62. Rowe, S., Alexander, N., Clydesdale, F., Applebaum, R., Atkinson, S., Black, R., Dwyer, J., Hentges, E., Higley, N., Lefevre, M., Lupton, J., Miller, S., Tancredi, D., Weaver, C., Woteki, C., and Wedral, E. International Life Sciences Institute (ILSI) North America Working Group on Guiding Principles. (2009). Funding food science and nutrition research: Financial conflicts and scientific integrity. Nutrition Review, 67: 264-272.
63. Sass, J. B. and Needleman, H. L. (2004). Industry testing of toxic pesticides on human subjects concluded no effect, despite the evidence. Environmental Health Perspectives, 112: A150-A151.
64. Schroter, S., Morris, J., Chaudhry, S., Smith, R., and Barratt, H. (2004). Does the type of competing interest statement affect readers' perceptions of the credibility of research? Randomised trial. British Medical Journal, 328: 742-743.
65. Shabir, H.W., Haider, N., Kumar, H., and Singh, N. B. (2010). Plant plastid engineering. Current Genomics, 11: 500-512.
66. Shamoo, A. S. and Resnik, D. B. (2009). Responsible Conduct of Research. 2nd ed. New York: Oxford University Press.
67. Shrader-Frechette, K. S. (2007). EPA's 2006 human-subjects rule for pesticide experiments. Accountability in Research, 14: 211-154.
68. Silverman, G. K., Loewenstein, G. F., Anderson, B. L., Ubel, P. A., Zinberg, S., and Schulkin, J. (2010). Failure to discount for conflict of interest when evaluating medical literature: A randomised trial of physicians. Journal of Medical Ethics, 36: 265-270.
69. Sismondo, S. (2008). Pharmaceutical company funding and its consequences: A qualitative systematic review. Contemporary Clinical Trials, 29: 109-113.
70. Smith, R. (2005). Medical journals are an extension of the marketing arm of pharmaceutical companies. PLoS Medicine, 2: e138.
71. Smith, R. (2006). Peer review: A flawed process at the heart of science and journals. Journal of the Royal Society of Medicine, 99: 178-182.
72. Society of Toxicology. (2008). Principles for Research Priorities in Toxicology. Available at http://www.toxicology.org/ai/gm/PrinResearch.asp. Last accessed: December 30, 2012.
73. Stelfox, H., Chua, G., O'Rourke, K., and Detsky, A. (1998). Conflict of interest in the debate over calcium channel antagonists. New England Journal of Medicine, 338: 101-106.
74. Volz, D. C. and Elliott, K. C. (2012). Mitigating conflicts of interest in chemical safety testing. Environmental Science and Technology, 46: 7937-7938.
75. Ziman, J. (2000). Real Science. Cambridge: Cambridge University Press.